2026 Domestic market price reference for Teclistamab

Teritusumab (Teclistamab-cqyv) is an immunotherapy drug developed by JANSSEN. It is mainly used to treat multiple myeloma (MM) and other blood system diseases. As a new type of immunotherapy, the selling price of teritusumab at home and abroad has certain differences and is affected by a variety of factors, such as exchange rate fluctuations and regional policies.

1. Domestic selling price reference

The generic drug teritusumab has been launched in the country but has not yet been included in medical insurance. Therefore, patients may need to pay out-of-pocket when purchasing. According to market information, the domestic selling price of teritusumab is approximately RMB 30,000 to RMB 40,000. Drug prices may fluctuate due to differences in domestic medical policies and price regulations. The drug has a specification of 30mg/3ml and is usually used to treat diseases such as multiple myeloma.

2. Overseas selling price reference

In overseas markets, the selling price of teritusumab is relatively high, and the prices vary greatly in different regions. Taking the European version of Teritusumab as an example, each box of 30mg/3ml is priced at more than RMB 10,000, while each box of 153mg/1.7ml (90mg/ml) is priced at more than RMB 50,000 (the price may fluctuate due to exchange rates). The price of the European version is usually slightly higher than in the domestic market, but still cheaper than in areas such as the United States.

3. Generic drug market

Currently, there are no generic versions of teritusumab available on the domestic and international markets. Because Teritusumab is still under patent protection, the production and sale of generic drugs is restricted. In the future, as patents expire or more manufacturers enter the market, the emergence of generic drugs may have an impact on prices, helping patients reduce the cost of treatment.

Keyword tags: Teritusumab, Teclistamab, Teclistamab, price, medical insurance, generic drugs, market price, immunotherapy, drug cost

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli